Possibly the reimbursement of R&D expenses relating to ATP 594, nothing else could be a candidate IMO. Inconsequential in the scheme of things as the potential working capital is drained by the high costs here.
Searcher2
Possibly the reimbursement of R&D expenses relating to ATP 594,...
Add ICN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.608M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| ICN (ASX) Chart |
Day chart unavailable